Article

Safety, Efficacy, and Immunogenicity of a Novel IgG Degrading Enzyme (KJ103): Results from Two Randomised, Blinded, Phase 1 Clinical Trials

2024-05-30

Abstract excerpt

<title>Abstract</title> The approved recombinant adeno-associated virus (AAV) intravenous drugs are limited by the high prevalence of pre-existing anti-AAV antibodies in the general population, which are known to restrict patients’ ability to receive gene therapy and limit transfection efficacy in vivo. Based on that, we developed a novel and low immunogenicity recombinant human immunoglobulin G degrading enzy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 877b1223-58c8-51aa-8cd3-bbcbbc02270c
DOI: 10.21203/rs.3.rs-4374237/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety, Efficacy, and Immunogenicity of a Novel IgG Degrading Enzyme (KJ103): Results from Two Randomised, Blinded, Phase 1 Clinical TrialsDOI 10.21203/rs.3.rs-4374237/v1Read

Rescuing AAV gene transfer from antibody neutralization with an IgG-degrading enzymeSemantic proximity Read

AAV vector manufacturing process design and scalability - Bending the trajectory to address vector-associated immunotoxicitiesSemantic proximity Read

Revolution of AAV in Drug Discovery: From Delivery System to Clinical ApplicationSemantic proximity Read

AAV delivered lysosome-targeting chimeras mediate sustained antibody depletion in vivoSemantic proximity Read

The Perspective of DMPK on Recombinant Adeno-Associated Virus-Based Gene Therapy: Past Learning, Current Support, and Future ContributionSemantic proximity Read

Infusion reactions to adeno‐associated virus (AAV)-based gene therapy: Mechanisms, diagnostics, treatment and review of the literatureSemantic proximity Read

Considerations for Preclinical Safety Assessment of Adeno-Associated Virus Gene Therapy ProductsSemantic proximity Read

An engineered IdeS variant with enhanced activity and performance for IgG degradationSemantic proximity Read

Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirementsSemantic proximity Read

Rapid Detection of AAV8 Binding Antibodies in Gene Therapy Candidates: Development of a Point-of-Care ApproachSemantic proximity Read

Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®)Semantic proximity Read

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read